Béa Applicator and Béa Cervical Cap Safety and Usability Study

Sponsor
StepOne Fertility (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05129553
Collaborator
(none)
40
1
7

Study Details

Study Description

Brief Summary

This is a Clinical Study Designed to Validate the Usability and Safety of the Over-the-counter (OTC) Béa Applicator and Béa Cervical Cap Device in a Home Use Environment.

Condition or Disease Intervention/Treatment Phase
  • Device: Béa Applicator and Béa Cervical Cap Device
N/A

Detailed Description

Female participants will undergo a baseline physical assessment performed by a physician at the study site. The participants will then be given the Béa Applicator and Béa Cervical Cap device with accompanying instructions and a semen collection pot. The participants will return home to use the device as per the Instruction for Use (IFU). The Béa Cervical Cap will remain in place for a minimum of 4 hours and a maximum of 6 hours. At the follow-up assessment, the investigator will investigate all primary objectives via a physical exam or via questioning the participant.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
Béa Applicator and Béa Cervical Cap Usability Study
Anticipated Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single Use

The participants will then be given the Béa Applicator and Béa Cervical Cap with accompanying instructions for single-use in a home use environment.

Device: Béa Applicator and Béa Cervical Cap Device
Single-use of the investigational device

Outcome Measures

Primary Outcome Measures

  1. Correctly place semen in the device [0.5 hrs]

    Participants indicate an ability to collect and transfer semen into the device in the intended use environment (at-home).

  2. Correctly inserting the device into the vagina [1 hrs]

    Participants indicate an ability to insert the device into the vagina, in the intended use environment (at-home).

  3. Correctly positioning of the device over the cervical os [4-6 hrs]

    A clinical examination by a physician to confirm the device is positioned over the cervical os.

  4. Correctly withdraw the device from the vagina [4-6 hrs]

    Participants indicate an ability to withdraw the device from the vagina with the use of the removal string.

  5. The device causes trauma or harm [4-6 hrs]

    After the device is removed from the vagina, a physician assessment via a speculum examination to determine if the device caused trauma or harm to the vaginal epithelium or cervix.

  6. Presence of semen in the cap [4-6 hrs]

    After the device is removed from the vagina, a physician assesses the presence of semen remaining in the cervical cap.

  7. Correctly dispose of the used device after use [4-6 hrs]

    Participants indicate an ability to dispose of the device after use.

  8. Correctly avoid sexual activity while the device is in place [4-6 hrs]

    Participants indicate an ability to avoid sexual activity while the device is on the cervical os.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • People who are able to and for whom it is medically safe to conceive

  • Heterosexual couples and individuals, of any race or ethnicity, who are sexually active

  • 18 - 40 years of age

  • Trying to conceive

  • Signed Informed Consent

  • Approximately nineteen per cent (19%) of participants will present with a retroverted uterus as found in the general female population.

Exclusion Criteria:
  • Vaginal prolapse (female)

  • Hysterectomy (female)

  • Erectile dysfunction (male)

  • Diagnosis and/or treatment of vaginitis or sexually transmitted infection (STI) within the last month

  • Colposcopy with biopsy surgery within the last three (3) months (female)

  • Treatment for dysplasia surgery within the previous three (3) months (female)

  • Vaginal/cervical surgery within the last three (3) months (female)

  • Current pregnancy (female)

  • Unable to read and understand English, as assessed by REALM

  • Presence of noticeable lesions, open sores, viral warts, and any other genital abnormalities (female & male)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • StepOne Fertility

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
StepOne Fertility
ClinicalTrials.gov Identifier:
NCT05129553
Other Study ID Numbers:
  • SOF63073301
First Posted:
Nov 22, 2021
Last Update Posted:
Nov 22, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Nov 22, 2021